Clinical analysis of acute myeloid leukemia with CBFB-MYH11-positive.
10.7534/j.issn.1009-2137.2013.02.009
- Author:
Ting-Ting CAO
1
;
Min-Hang ZHOU
;
Lei YUAN
;
Qian WANG
;
Li-Ping DOU
;
Yuan-Yuan XU
;
Nan WANG
;
Li-Li WANG
;
Li YU
;
Yu JING
Author Information
1. Department of Hematology, General Hospital of Chinese PLA, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Female;
Humans;
Immunophenotyping;
Induction Chemotherapy;
Leukemia, Myeloid, Acute;
diagnosis;
drug therapy;
genetics;
Male;
Middle Aged;
Oncogene Proteins, Fusion;
genetics;
metabolism;
Prognosis;
Retrospective Studies;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(2):305-310
- CountryChina
- Language:Chinese
-
Abstract:
The study was aimed to investigate the clinical characteristics of acute myeloid leukemia (AML) with CBFB-MYH11 gene. The clinical data of 12 cases were analyzed retrospectively, including age, clinical characteristics, immunophenotype, treatment protocols and efficacy as well as the prognosis. The results indicated that 12 patients with CBFB-MYH11 were detected in 293 AML patients. The median age of the 12 patients was 32.5 (21 - 57) years old. According to French-American-British (FAB) classification, 66.7% (8/12) patients was diagnosed as M4Eo and 33.3% patients was diagnosed as M4. At new diagnosis, the median WBC count was 19.8×10(9)/L (2.46 - 164.30×10(9)/L). The WBC count > 100×10(9) was found in 16.7% patients (2/12). The complete remission (CR) rate after 1 and 2 cycles of induction chemotherapy were 83.3% and 16.7% respectively, so the total CR rate was 100%. Estimated 5-year relapse-free survival (RFS) and overall survival (OS) were 80% and 83%, respectively. It is concluded that patients with CBFB-MYH11 are usually M4Eo and M4. Patients with this fusion gene are often associated with high frequency of CD33, CD34, CD117, HLA-DR, CD15, CD64 and CD14 expression. Patients with CBFB-MYH11 have a tendency of higher CR rate, longer RFS and OS.
